Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.
Esparragosa Vazquez I, Sanson M, Chinot OL, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, Cartalat S, Tabouret E, Appay R, Bonneville-Levard A, Darlix A, Meyronet D, Barritault M, Gueyffier F, Remontet L, Maucort-Boulch D, Honnorat J, Dehais C, Ducray F; POLA Network. Esparragosa Vazquez I, et al. Among authors: rivoirard r. Neurooncol Adv. 2024 May 27;6(1):vdae078. doi: 10.1093/noajnl/vdae078. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38855053 Free PMC article.
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Esparragosa Vazquez I, Ndiaye M, Di Stefano AL, Younan N, Larrieu-Ciron D, Seyve A, Picart T, Meyronet D, Boutet C, Vassal F, Carpentier C, Figarella-Branger D, Dehais C, Forest F, Rivoirard R, Ducray F; POLA network. Esparragosa Vazquez I, et al. Among authors: rivoirard r. Eur J Neurol. 2023 Sep;30(9):2879-2883. doi: 10.1111/ene.15873. Epub 2023 May 31. Eur J Neurol. 2023. PMID: 37204066
The Impact of an Enrolment in Clinical Trial on Tolerance and Pathological Response for Patients Treated by Neoadjuvant MVAC Against an Invasive Bladder Cancer. A Retrospective Comparative Study.
Guignand A, Bouleftour W, Vassal C, Tinquaut F, Rivoirard R, Guillot A. Guignand A, et al. Among authors: rivoirard r. Clin Genitourin Cancer. 2024 Feb;22(1):e14-e21.e3. doi: 10.1016/j.clgc.2023.06.006. Epub 2023 Jun 15. Clin Genitourin Cancer. 2024. PMID: 37400296
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Gauduchon T, Kfoury M, Lorusso D, Floquet A, Ventriglia J, Salaun H, Moubarak M, Rivoirard R, Polastro L, Favier L, You B, Berton D, de la Motte Rouge T, Mansi L, Abdeddaim C, Prulhiere K, Lancry Lecomte L, Provansal M, Dalban C, Ray-Coquard I. Gauduchon T, et al. Among authors: rivoirard r. Gynecol Oncol. 2023 Jun;173:98-105. doi: 10.1016/j.ygyno.2023.04.002. Epub 2023 Apr 25. Gynecol Oncol. 2023. PMID: 37105063
Body surface area capping may not improve cytotoxic drugs tolerance.
Bouleftour W, Viard A, Mery B, Chaux R, Magne N, Simoens X, Rivoirard R, Forges F. Bouleftour W, et al. Among authors: rivoirard r. Sci Rep. 2021 Jan 28;11(1):2431. doi: 10.1038/s41598-021-81792-6. Sci Rep. 2021. PMID: 33510207 Free PMC article.
Effectiveness of a nurse-led telephone follow-up in the therapeutic management of patients receiving oral antineoplastic agents: a randomized, multicenter controlled trial (ETICCO study).
Bouleftour W, Muron T, Guillot A, Tinquaut F, Rivoirard R, Jacquin JP, Saban-Roche L, Boussoualim K, Tavernier E, Augeul-Meunier K, Collard O, Mery B, Pupier S, Oriol M, Bourmaud A, Fournel P, Vassal C. Bouleftour W, et al. Among authors: rivoirard r. Support Care Cancer. 2021 Aug;29(8):4257-4267. doi: 10.1007/s00520-020-05955-3. Epub 2021 Jan 7. Support Care Cancer. 2021. PMID: 33409726 Clinical Trial.
57 results